THOMAS OKRASINSKI: Open Payments
NPI 1700252095 · EVANSTON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 13 payments from 10 companies in 2025. Trend: 2023 $415 · 2024 $531 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $148 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 1 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $27 |
| Alexion Pharmaceuticals, Inc. | 1 | $27 |
| Calliditas Therapeutics US Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Novo Nordisk Inc | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
Products named: Fabhalta, Kerendia, FARXIGA, JARDIANCE, ULTOMIRIS, TARPEYO, ACTHAR, JYNARQUE.
Industry payments across IL — which companies pay providers there.
